Dr Joanna Achinger-Kawecka
Dr Joanna Achinger-Kawecka’s research focuses on investigating the role of the 3D epigenome in cancer, particularly in driving tumour progression and treatment resistance in breast and prostate cancer. Joanna completed her PhD at the University of Tuebingen, Germany, investigating microRNA signatures as predictive biomarkers for breast cancer treatment outcome. Following her PhD, Joanna joined the laboratory of Professor Susan Clark at the Garvan Institute of Medical Research, where she established cutting-edge experimental and computational approaches to study the 3D genome organisation during development and progression of cancer.
Awards
- 2011FP7 Marie Curie Initial Training Network “Fighting Drug Failure” Fellowship
- 2015Best Oral Presentation Prize - 23rd St Vincent’s Campus Research Symposium
- 2016Heliflite Young Explorer Award
- 2017The Ian Potter Foundation Travel Grant
- 2018CASS Foundation Travel Grant
- 2019EMBO Travel Award
- 2019Estee Lauder Companies’ Breast Cancer Campaign Award
- 2020Cancer Council NSW Project Grant (2020 - 2022)
- 2020UNSW Cellular Genomics Futures Institute Seed Grant (2020 - 2021)
- 2021NBCF Fellowship (2021 - 2024)
- 2022UNSW Cancer Theme EMCR Seed Grant
- 2023PCFA Priority Impact Research Award Young Investigator Award
- 2023St Vincent's Campus Research Symposium Rising Star Award
Selected Publications
See all publications- 2023Science advances10.1126/sciadv.abp8314
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma.
- 2022Cancers10.3390/cancers14030474
Epigenetic Therapies and Biomarkers in Breast Cancer.
- 2021Cell reports10.1016/j.celrep.2021.109722
DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity.
- 2021Clinical epigenetics10.1186/s13148-021-01023-7
BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer.
- 2020Nature communications10.1038/s41467-019-14098-x
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.